Mundipharma name GSK veteran as new Senior Vice President & CFO
pharmafile | November 19, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cambridge, Mundipharma, arnaud breabout, cfo, svp, wsenior vice president
The Mundipharma network today confirmed the appointment of Arnaud Breabout, to the position of Senior Vice President & Chief Financial Officer.
Breabout will report to Mundipharma President & Chief Executive Officer (CEO), Alberto Martinez.
Coming from a career at British multinational GSK, the Harvard Business School grad brings with him a wealth of international healthcare and fast moving consumer goods (FMCG) experience.
Mundipharma President & CEO, Alberto Martinez, commented: “We are extremely pleased to fill this key strategic role with an experienced and motivated individual with strong leadership, financial and people skills. I look forward to working with Arnaud as we continue our focus on delivering innovation and commercial excellence through partnerships.”
Having joined GSK in 2002, Breabout took on roles of increasing seniority before taking on the position of Vice President and CFO GSK Global Functions and Investments in 2014.
While at GSK, he held a number of senior Finance leadership positions including Vice President Pharmaceutical R&D Pipeline, CFO Biopharmaceuticals, CFO Vaccines North America and CFO GSK Consumer Healthcare France.
Prior to his 16 year career at the British multinational, Breabout took on central roles in the Corixa Corporation, Procter & Gamble, and Bristol-Myers Squibb. However the French national began his career at Price Waterhouse (PWC) working in both Paris and the UK.
Commenting on his appointment, Arnaud said: “This is an exciting time for Mundipharma. I’m delighted to be joining such an ambitious, talented and agile team working on an innovative development pipeline and diverse portfolio of medicines. I look forward to deploying my international experience in growing and transforming businesses, to optimise the financial functions across the Mundipharma network.”
European Commission has moved to expand the existing approved indication for Mundipharma’s Invokana (canagliflozin), making …
AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the …